A full house, sharp discussions, and an afternoon in which science and industry visibly strengthened one another. The Dutch Medicines Winter Afternoon demonstrated that Groningen is not only a strong geographical spot, but also a substantive force within the Dutch life sciences landscape. The event, organized by FIGON (Federation for Innovative Drug Research Netherlands) in collaboration with LIFE Cooperative, brought professionals from across the Netherlands to the north.
Researchers, entrepreneurs, developers, and clinical experts gathered around one shared ambition: to bring innovative medicines to patients faster, smarter, and better.Klaas Poelstra, Chair of FIGON, looks back positively on the event: “It was great to see local businesses in the health sector and leading academic scientists engaging in conversation with one another. They have so much to gain from each other.“
What became particularly clear during the Dutch Medicines Winter Afternoon was how rapidly the field of drug development is evolving, and how essential collaboration has become. At a time when therapies are increasingly targeted, complex, and costly, the focus is shifting from only what we develop to how we do so: more intelligently, more sustainably, and better aligned with patient needs.
This broader context was already reflected in the opening remarks by Klaas Poelstra, who emphasized the importance of continued innovation for the Netherlands’ competitive position and patient care. On behalf of the LIFE Cooperative, Robert Hof highlighted that regional collaboration is a decisive factor: by bringing science, entrepreneurship, and clinical practice closer together, real acceleration can be achieved.
The first substantive contributions made it clear that innovation today is not only about new molecules, but also about new delivery methods. Rob Steendam demonstrated how long-acting microspheres can improve treatment adherence and reduce patient burden. Jaap Wieling showed how inhalation technology is evolving into a platform for both local and systemic therapies. Through her research on polyelectrolyte coacervates, Marleen Kamperman placed these innovations within a fundamental scientific framework.
After the break, the discussion shifted to clinical translation and advanced nanomedicines. Flávia Sousa illustrated how polymer-based nanomedicines contribute to targeted brain delivery. Ad Roffel underscored the importance of robust pharmacokinetic studies in an era where the demands for evidence continue to increase. Erik Frijlink reflected on innovation within both existing and new delivery systems, while Helder Santos outlined the potential of RNA delivery via nanotechnology for cardiac tissue repair.
During the closing networking reception, it became clear what participants had gained from the afternoon. As Robert Hof, Board Member of the LIFE Cooperative, put it:
“The FIGON Winter Afternoon was an excellent event with distinguished speakers and strong engagement. We look forward to the next edition and extend our sincere thanks to Klaas Poelstra and FIGON for hosting the event in the Northern Netherlands.”
The common thread throughout the afternoon was therefore unmistakable: the future of medicines does not lie within a single discipline, but in the connections between them. In a time of increasing healthcare pressure, rapid technological advancement, and international competition, such collaboration is not a luxury—it is a necessity.
The Dutch Medicines Winter Afternoon showed that this collaboration is firmly rooted in the Northern Netherlands and that Groningen is positioning itself emphatically as a breeding ground and accelerator for innovative drug development.
Innovation in medicines takes center stage on Thursday, 26 February during the Dutch Medicines Winter Afternoon, an inspiring event organized by FIGON (Federation for Innovative Drug Research Netherlands) in collaboration with the LIFE Cooperative.
A unique collaboration for an urgent problem Pharmaceutical residues in groundwater and surface water pose a growing problem. Due to population ageing and the rise in chronic conditions, medication use is expected to increase significantly in the coming years. This creates an increasing threat to environmental and human health, particularly in Northern Netherlands as one of the most rapidly ageing regions. What makes this project unique is that parties from the water technology sector, the Life Science & Health sector, and the healthcare sector jointly work with SMEs to develop innovative solutions. Under the leadership of lead partner TCNN, these domains are brought together, resulting in a powerful acceleration of both knowledge development and the actual implementation of innovative solutions.Project objectives Under the guidance of work package leaders Water Alliance, LIFE Cooperative, CEW, and UMCG, the partners focus on elaborating existing problem areas. For each problem area, SMEs will be sought that can provide solutions across four interconnected pillars: • Advanced water treatment: development and application of new technologies to effectively remove pharmaceutical residues from water. • More sustainable medicines and administration: innovation in pharmaceutical products and delivery methods that reduce environmental impact. • Improved prescribing behaviour and medication adherence: awareness-raising and training to prevent unnecessary medication use. • Active knowledge sharing: intensive collaboration, communication, and dissemination of best practices within the region and beyond.Impact after three years During the kick-off, participants emphasised the shared ambitions they aim to achieve: • A structural connection between the water, pharmaceutical, and healthcare sectors• Measurable reduction in medication use through more conscious prescribing• Sustainability as an integral and self-evident part of medication use and policy In addition to these societal benefits, the project aims to create 75 new jobs and to provide targeted support to at least 30 companies. The developed solutions can also be applied nationally and internationally. This integrated approach positions Northern Netherlands as a national and international frontrunner in tackling pharmaceutical residues in water.Partners The project is a collaboration between: TCNN (lead partner), LIFE Cooperative, Wilhelmina Ziekenhuis Assen, Martini Ziekenhuis, Isala Ziekenhuis, University of Groningen, UMCG, Frisius MC, Water Alliance, Centre of Expertise Watertechnology (CEW), Wetterskip Fryslân, Waterschap Noorderzijlvest, Province of Groningen, Province of Drenthe, Province of Fryslân, SNN, and Medicijnresten uit Water Noord-Nederland. Together, we are building a healthy, sustainable, and economically strong Northern Netherlands.
With the launch of LIFE Capital, the Northern Netherlands gains a powerful collaboration platform that brings together companies, talent, and knowledge institutions in the fast-growing Life Sciences & Health sector. During a special launch dinner on Tuesday, November 25 at LIFE Cooperative member Polyvation on the Groningen Campus, not only was the new brand unveiled, but an ambitious vision for the future was also presented. LIFE Capital, formerly LIFE Academy, marks the next phase of the LIFE Cooperative: shifting from a focus on training alone to a broadly supported collaboration platform for human capital. “With LIFE Capital we are taking the next step in strengthening our sector,” says Melloney Dröge, board member of the LIFE Cooperative. “We are bringing companies, talent, and knowledge together into one ecosystem where growth, learning, and innovation go hand in hand. We are aiming for a joint approach to the human capital challenges of our sector. In this way, we are building a region where you can truly move forward for a lifetime, literally and figuratively.”From LIFE Academy to LIFE Capital The transition from LIFE Academy to LIFE Capital is more than a name change. The new brand reflects the organization’s growth and its ambition to look beyond training alone. LIFE Capital will become the linchpin of human capital in the Life Sciences & Health sector: it connects talent, companies, and knowledge, accelerates collaboration, and strengthens the position of the Northern Netherlands as a breeding ground for innovation and talent. A long and healthy life: that is ultimately what Life Sciences & Health is all about. Thanks to innovations from companies in this sector, diseases are detected sooner, treated more effectively, and sometimes even prevented. From breakthrough therapies to keeping healthcare affordable and accessible, the business community acts as the engine behind life-changing progress. LIFE Capital aims to strengthen that foundation by investing in people, knowledge, and collaboration. “LIFE Capital helps companies move forward, but also strengthens the image and visibility of our sector,” says Sven Stielstra, Manager of LIFE Capital. “In this way, we show what Life Sciences & Health truly stands for and make the sector attractive to new talent and innovative companies. Over the next ten years, we will attract €50 million for human capital. In this first year alone, we have already realized €6.6 million through regional and national funds.”Looking ahead: recruitment campaign and pilots in 2026 Today, the day after the launch dinner, LIFE Capital’s recruitment campaign begins. This campaign focuses on attracting participants for the first pilot modules, which will start in spring 2026. These modules were developed thanks to an intensive and unique collaboration between Hanze, UMCG, and various companies within the sector. By combining knowledge and practical experience, top-notch programmes have been created that will be tested in the coming period. After the pilot phase, the modules will be further developed and made more widely available later in 2026 to everyone in the Northern Netherlands who wishes to contribute to a strong Life Sciences & Health ecosystem.About LIFE Capital LIFE Capital is the collaboration platform of the LIFE Cooperative, a network of more than 60 companies in the Life Sciences & Health sector. The platform connects organisations around shared human capital challenges and develops solutions that attract, develop, and retain talent. What started ten years ago as separate initiatives within the cooperative has grown into a strategic programme in which companies, knowledge institutions, and governments work together on a structural basis. With activities ranging from joint training and HR networks to new educational programmes and labour market research, LIFE Capital works towards one goal: a strong, agile region in which talent in life sciences & health can continue to grow with the right skills. Move people forward.About LIFE Cooperative The LIFE Cooperative stimulates innovation in the life sciences by facilitating collaboration between entrepreneurs, researchers, and investors. Through various programmes and events, LIFE promotes the development of technologies that improve health and well-being. The cooperative represents more than 60 companies in the Northern Netherlands, ranging from ambitious startups and innovative SMEs to international players. Together, they represent approximately 5,000 FTEs and a turnover of €500 million.
